ESCRS - Supplement: Keys to Maximizing Outcomes for Today’s PresbyopiaCorrection Cataract Patients
Supplements

Supplement: Keys to Maximizing Outcomes for Today’s PresbyopiaCorrection Cataract Patients

Supplement: Keys to Maximizing Outcomes for Today’s PresbyopiaCorrection Cataract Patients

The European Society of Cataract and Refractive Surgeons (ESCRS) conducts an annual Clinical Trends Survey to understand the practice pat-terns and clinical opinion of its delegates. In 2021, during the 39th ESCRS Congress, the seventh annual survey posed 154 questions pertaining to cataract and refractive surgery, the ocular surface, and glaucoma, and received responses from 1574 delegates. The insights gained from these responses provide a snapshot of clinical practice in the real world and, when consolidated over the past 6 years, an opportunity to see how the field is evolving.

Supplement: Keys to Maximizing Outcomes for Today’s PresbyopiaCorrection Cataract Patients

Tags: cataract and refractive
Latest Articles
Committing to a More Equitable Ophthalmology

Charity Committee enhances ESCRS’s reputation as a socially responsible society.

Read more...

Virtual Community Unites Ukrainian Eye Specialists

Microlearning platform proves vital to saving eyes and lives in areas of conflict.

Read more...

ESCRS Survey Shifts Industry Dial

Annual survey reveals trends and issues regarding the digital OR.

Read more...

Always Measure the Epithelium!

Epithelium thickness mapping key to better refractive outcomes.

Read more...

Brave New World of AI

More applications for anterior segment anticipated.

Read more...

Advancing Vision Research

National Eye Institute initiatives encourage AI-based innovations and data interoperability.

Read more...

Best Candidates for Phakic EDOF IOLs?

Patient profile suggests limits for phakic EDOF approach.

Read more...

Knowing Iris Repair: Iris Repair with Prosthetic Devices

New devices on the market expand available options when iris tissue is insufficient.

Read more...

Targeting the Kallikrein-Kinin System to Treat DME

Novel oral plasma kallikrein inhibitor shows promise in early clinical trial.

Read more...

Faricimab VOYAGER Study

Real-world experience with faricimab for treatment-naïve nAMD and DME is underway.

Read more...